News > Coronavirus: Bharat Biotech’s nasal vaccine gets approval for phase 2 clinical trial

Coronavirus: Bharat Biotech’s nasal vaccine gets approval for phase 2 clinical trial

Scroll | 14/08/2021 08:59 AM | Click to read full article

Biotechnology company Bharat Biotech on Friday received the Drugs Controller General of India’s approval to conduct phase 2 clinical trials of its nasal vaccine against Covid-19, the Centre said. Unlike most vaccines that are administered by injection through the muscle or subcutaneous layer (the layer of skin between the dermis and the epidermis) route, intranasal vaccines are given as a nasal spray and offer a needle-free approach.

The intranasal vaccine developed by Bharat Biotech is the first of its kind to receive approval for phase 2 clinical trial in India.